Created at Source Raw Value Validated value
June 25, 2024, noon usa

inclusion criteria: to be included in this study, each individual must satisfy all of the following criteria: 1. adults 18 to 49 years of age, inclusive, at screening 2. willing and able to give informed consent prior to study enrollment and to comply with study procedures. 3. participants of childbearing potential (defined as any participant who has experienced menarche and who is not surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea at least 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (eos) visit or agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through the eos visit. 4. is medically stable, as determined by the investigator (based on review of health status, vital signs \[to include body temperature\], medical history, and targeted physical examination \[to include body weight\]). vital signs must be within medically acceptable ranges prior to the study vaccination 5. agree to not participate in any other sars-cov-2 prevention or treatment trials for the duration of the study. note: for participants who become hospitalized with coronavirus disease 2019 (covid-19), participation in investigational treatment studies is permitted. 6. documented receipt of either 2 or 3 doses of the investigational novavax vaccine with matrix-m adjuvant (nvx- cov2373); or documented receipt of a full course of an fda-authorized/approved covid-19 vaccine; or documented receipt of a full course of heterologous covid-19 vaccines mentioned above. the most recent dose must have been administered at least 6 months prior to study vaccination.

inclusion criteria: to be included in this study, each individual must satisfy all of the following criteria: 1. adults 18 to 49 years of age, inclusive, at screening 2. willing and able to give informed consent prior to study enrollment and to comply with study procedures. 3. participants of childbearing potential (defined as any participant who has experienced menarche and who is not surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea at least 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (eos) visit or agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through the eos visit. 4. is medically stable, as determined by the investigator (based on review of health status, vital signs \[to include body temperature\], medical history, and targeted physical examination \[to include body weight\]). vital signs must be within medically acceptable ranges prior to the study vaccination 5. agree to not participate in any other sars-cov-2 prevention or treatment trials for the duration of the study. note: for participants who become hospitalized with coronavirus disease 2019 (covid-19), participation in investigational treatment studies is permitted. 6. documented receipt of either 2 or 3 doses of the investigational novavax vaccine with matrix-m adjuvant (nvx- cov2373); or documented receipt of a full course of an fda-authorized/approved covid-19 vaccine; or documented receipt of a full course of heterologous covid-19 vaccines mentioned above. the most recent dose must have been administered at least 6 months prior to study vaccination.

July 19, 2022, noon usa

inclusion criteria: to be included in this study, each individual must satisfy all of the following criteria: adults 18 to 49 years of age, inclusive, at screening willing and able to give informed consent prior to study enrollment and to comply with study procedures. participants of childbearing potential (defined as any participant who has experienced menarche and who is not surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (eos) visit or agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through the eos visit. is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). vital signs must be within medically acceptable ranges prior to the study vaccination agree to not participate in any other sars-cov-2 prevention or treatment trials for the duration of the study. note: for participants who become hospitalized with coronavirus disease 2019 (covid-19), participation in investigational treatment studies is permitted. documented receipt of either 2 or 3 doses of the investigational novavax vaccine with matrix-m adjuvant (nvx- cov2373); or documented receipt of a full course of an fda-authorized/approved covid-19 vaccine; or documented receipt of a full course of heterologous covid-19 vaccines mentioned above. the most recent dose must have been administered at least 6 months prior to study vaccination.

inclusion criteria: to be included in this study, each individual must satisfy all of the following criteria: adults 18 to 49 years of age, inclusive, at screening willing and able to give informed consent prior to study enrollment and to comply with study procedures. participants of childbearing potential (defined as any participant who has experienced menarche and who is not surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (eos) visit or agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through the eos visit. is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). vital signs must be within medically acceptable ranges prior to the study vaccination agree to not participate in any other sars-cov-2 prevention or treatment trials for the duration of the study. note: for participants who become hospitalized with coronavirus disease 2019 (covid-19), participation in investigational treatment studies is permitted. documented receipt of either 2 or 3 doses of the investigational novavax vaccine with matrix-m adjuvant (nvx- cov2373); or documented receipt of a full course of an fda-authorized/approved covid-19 vaccine; or documented receipt of a full course of heterologous covid-19 vaccines mentioned above. the most recent dose must have been administered at least 6 months prior to study vaccination.